AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24125113 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 3252
Study 24125113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3252
Study 20869201 — intervention group
Group type: EXPERIMENTAL
Intervention: Rope jumping exercise (controlled with RPE values ranging from 11 to 15)
Number of subjects: 0
Study 20869201 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 0
Study 19099850 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary surfactant (PS) treatment in preterm infants (n=28)
Number of subjects: 177
Study 19099850 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary surfactant (PS) treatment in term and late-preterm infants (n=8)
Number of subjects: 177
Study 19099850 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation (MV) in preterm infants
Number of subjects: 177
Study 19099850 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation (MV) in term and late-preterm infants
Number of subjects: 177
Study 19099850 — intervention group
Group type: COMPARATOR
Intervention: Comparison of OI between preterm and term/late-preterm infants
Number of subjects: 177
Study 19099850 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of pneumothorax in preterm infants
Number of subjects: 177
Study 19099850 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of pneumothorax in term and late-preterm infants
Number of subjects: 177
Study 19099850 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of persistent pulmonary hypertension of the newborn (PPHN) in preterm infants
Number of subjects: 177
Study 19099850 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of persistent pulmonary hypertension of the newborn (PPHN) in term and late-preterm infants
Number of subjects: 177
Study 16313122 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingxue Granules (QX)
Number of subjects: 20
Study 16313122 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (WM group)
Number of subjects: 20
Study 12451480 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubitecan 1.5 mg/m(2) per day orally
Number of subjects: 14
Study 10519494 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotensive mean arterial blood pressure range of 45‐55 mmHg
Number of subjects: 235
Study 10519494 — intervention group
Group type: COMPARATOR
Intervention: Less hypotensive mean arterial blood pressure range of 55‐70 mmHg
Number of subjects: 235
Study 8813496 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone (100 mg per day initially, dosage reduction every 3 days; n = 15)
Number of subjects: 48
Study 8813496 — intervention group
Group type: COMPARATOR
Intervention: Thiamine (100 mg per day; n = 33)
Number of subjects: 48
Study 1827103 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg orally (500 mg for lung tissue), administered every 12 h for three days.
Number of subjects: 174
Study 1827103 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin 150 mg orally, administered every 12 h for three days.
Number of subjects: 174
Study 7094857 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra maternal-infant contact during the first postpartum hour
Number of subjects: 60
Study 7094857 — intervention group
Group type: COMPARATOR
Intervention: Routine contact
Number of subjects: 60
Study 31399091 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF6001 800 μg
Number of subjects: 61
Study 31399091 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF6001 1600 μg
Number of subjects: 61
Study 31399091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 29917125 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruent Pictorial Health Warning Labels (PWLs)
Number of subjects: 320
Study 29917125 — intervention group
Group type: COMPARATOR
Intervention: Incongruent Pictorial Health Warning Labels (PWLs)
Number of subjects: 320
Study 29917125 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Congruent and Incongruent PWLs
Number of subjects: 320
Study 29141843 — intervention group
Group type: EXPERIMENTAL
Intervention: STABLE‐SR
Number of subjects: 229
Study 29141843 — intervention group
Group type: COMPARATOR
Intervention: STEPWISE
Number of subjects: 229
Study 26712982 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg capsule 1 hour before surgery
Number of subjects: 200
Study 26712982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 26712982 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 200
Study 23782920 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine CAPs exposure
Number of subjects: 15
Study 23782920 — intervention group
Group type: EXPERIMENTAL
Intervention: Coarse CAPs exposure
Number of subjects: 15
Study 23782920 — intervention group
Group type: COMPARATOR
Intervention: HEPA-filtered medical air (control)
Number of subjects: 15
Study 21943111 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive fluid strategy (4 ml/kg/hour of Ringer's lactate solution)
Number of subjects: 88
Study 21943111 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluid strategy (12 ml/kg/hour of Ringer's lactate solution)
Number of subjects: 88
Study 18588512 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEi (angiotensin‐converting enzyme inhibitors)
Number of subjects: 0
Study 18588512 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 0
Study 18588512 — intervention group
Group type: EXPERIMENTAL
Intervention: ARBs (angiotensin II receptor blockers)
Number of subjects: 0
Study 16515395 — intervention group
Group type: EXPERIMENTAL
Intervention: HTT-blocking antidepressants (SSRIs, TCAs)
Number of subjects: 109
Study 16515395 — intervention group
Group type: COMPARATOR
Intervention: Mirtazapine
Number of subjects: 109
Study 15260082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.3 mg/kg/hr) and Propofol (initial rate of 10 mg/kg/hr)
Number of subjects: 20
Study 15260082 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) and Propofol (initial rate of 10 mg/kg/hr)
Number of subjects: 20
Study 11729708 — intervention group
Group type: EXPERIMENTAL
Intervention: Infloran Berna (10^9 Lactobacillus acidophilus and 10^9 Bifidobacterium infantis, one capsule tid for 4 days)
Number of subjects: 100
Study 11729708 — intervention group
Group type: COMPARATOR
Intervention: Control group (parenteral rehydration only)
Number of subjects: 100
Study 9228366 — intervention group
Group type: EXPERIMENTAL
Intervention: NIVS with a nasal ventilatory support system (BiPAP) during 1 h
Number of subjects: 19
Study 9228366 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NIVS)
Number of subjects: 19
Study 8219661 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acid based lipid emulsion (100 ml/day with 2.1 g eicosapentaenoic (EPA) and 21 g docosahexaenoic acid (DHA))
Number of subjects: 20
Study 8219661 — intervention group
Group type: COMPARATOR
Intervention: Conventional n-6 lipid emulsion (EPA + DHA < 0.1 g/100 ml)
Number of subjects: 20
Study 2887189 — intervention group
Group type: EXPERIMENTAL
Intervention: epanolol 400 mg
Number of subjects: 8
Study 2887189 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol 100 mg
Number of subjects: 8
Study 2887189 — intervention group
Group type: COMPARATOR
Intervention: epanolol 200 mg
Number of subjects: 8
Study 2887189 — intervention group
Group type: EXPERIMENTAL
Intervention: epanolol 400 mg and atenolol 100 mg
Number of subjects: 8
Study 2887189 — intervention group
Group type: EXPERIMENTAL
Intervention: pharmacological and non-pharmacological interventions
Number of subjects: 8
Study 31586176 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial 1A (common procedure)
Number of subjects: 411
Study 31586176 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial 1B
Number of subjects: 411
Study 31586176 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial 2C
Number of subjects: 411
Study 31586176 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial 3A
Number of subjects: 411
Study 31586176 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial 3D
Number of subjects: 411
Study 31586176 — intervention group
Group type: COMPARATOR
Intervention: Trial 2 (Arm C/D)
Number of subjects: 411
Study 30406067 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditative movement (MM) training
Number of subjects: 0
Study 30406067 — intervention group
Group type: COMPARATOR
Intervention: Health education (HE) videos
Number of subjects: 0
Study 27072143 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC)
Number of subjects: 60
Study 27072143 — intervention group
Group type: COMPARATOR
Intervention: Immediate release morphine (IRM)
Number of subjects: 60
Study 27072143 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (OTFC and IRM)
Number of subjects: 60
Study 27072143 — intervention group
Group type: COMPARATOR
Intervention: OTFC
Number of subjects: 60
Study 27072143 — intervention group
Group type: COMPARATOR
Intervention: IRM
Number of subjects: 60
Study 24939433 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg isoflavones/day (supplements)
Number of subjects: 103
Study 24939433 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 mg isoflavones/day (soy foods)
Number of subjects: 103
Study 24939433 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubling isoflavone intake
Number of subjects: 103
Study 24939433 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-individual variation
Number of subjects: 103
Study 23933107 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for 12 sessions
Number of subjects: 46
Study 23933107 — intervention group
Group type: COMPARATOR
Intervention: Acceptance and Commitment Therapy (ACT) for 12 sessions
Number of subjects: 46
Study 23933107 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall predictor of treatment outcome
Number of subjects: 46
Study 20505108 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlapping mazes
Number of subjects: 0
Study 20505108 — intervention group
Group type: COMPARATOR
Intervention: Non-overlapping mazes
Number of subjects: 0
Study 18840817 — intervention group
Group type: COMPARATOR
Intervention: Biomarker assay
Number of subjects: 0
Study 18840817 — intervention group
Group type: COMPARATOR
Intervention: Rigorous standards for biomarker evaluation
Number of subjects: 0
Study 16619561 — intervention group
Group type: COMPARATOR
Intervention: sEGFR levels below 45 ng/mL
Number of subjects: 101
Study 16619561 — intervention group
Group type: EXPERIMENTAL
Intervention: sEGFR levels below 45 ng/mL and elevated serum HER‐2/neu ECD (>15 ng/mL)
Number of subjects: 101
Study 16619561 — intervention group
Group type: EXPERIMENTAL
Intervention: sEGFR levels below 45 ng/mL in estrogen receptor-positive tumors
Number of subjects: 101
Study 16619561 — intervention group
Group type: EXPERIMENTAL
Intervention: sEGFR levels below 45 ng/mL in estrogen receptor-positive tumors with elevated HER‐2/neu ECD
Number of subjects: 101
Study 16619561 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy treatment
Number of subjects: 101
Study 12764215 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychotherapy
Number of subjects: 59
Study 12764215 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (no control group mentioned)
Number of subjects: 59
Study 10888102 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioflo pericardial bioprosthesis
Number of subjects: 170
Study 10888102 — intervention group
Group type: COMPARATOR
Intervention: Carpentier‐Edwards (CE) supra‐annular porcine bioprosthesis
Number of subjects: 170
Study 8863088 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic illness (females)
Number of subjects: 162
Study 8863088 — intervention group
Group type: COMPARATOR
Intervention: Control group (females)
Number of subjects: 162
Study 8863088 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic illness (males)
Number of subjects: 162
Study 8863088 — intervention group
Group type: COMPARATOR
Intervention: Control group (males)
Number of subjects: 162
Study 2017337 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A: vancomycin 250 mg, tobramycin 75 mg, colistin 1 million IU, nystatin
Number of subjects: 0
Study 2017337 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B: vancomycin 125 mg, tobramycin 75 mg, colistin 1 million IU, nystatin
Number of subjects: 0
Study 2017337 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen C: colistin 1 million IU, nystatin
Number of subjects: 0
Study 618711 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroma-free hemoglobin (SFH) infusion (250 ml administered slowly intravenously)
Number of subjects: 10
Study 618711 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroma-free hemoglobin (SFH) infusion
Number of subjects: 10
Study 618711 — intervention group
Group type: COMPARATOR
Intervention: Serum albumin (250 ml administered to control group)
Number of subjects: 10
Study 31386219 — intervention group
Group type: EXPERIMENTAL
Intervention: siponimod
Number of subjects: 0
Study 31386219 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 28765029 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-stage surgery (combined cervical and thoracic decompression via a single posterior incision)
Number of subjects: 30
Study 28765029 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-stage surgery (sequential cervical and thoracic decompressions)
Number of subjects: 30
Study 28765029 — intervention group
Group type: COMPARATOR
Intervention: Both surgical approaches (combined and staged)
Number of subjects: 30
Study 25840644 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 207
Study 25840644 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents
Number of subjects: 207
Study 25840644 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 207
Study 25840644 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-diabetic patients
Number of subjects: 207
Study 23934185 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic tonsillectomy with bipolar cauterization
Number of subjects: 100
Study 23934185 — intervention group
Group type: COMPARATOR
Intervention: Harmonic scalpel tonsillectomy
Number of subjects: 100
Study 21563715 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental education, home evaluation, and lead remediation (intervention group)
Number of subjects: 314
Study 21563715 — intervention group
Group type: COMPARATOR
Intervention: Standard lead education (control group)
Number of subjects: 314
Study 21563715 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention groups (parental education, home evaluation, and lead remediation)
Number of subjects: 314
Study 19306033 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum beverage
Number of subjects: 19
Study 19306033 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat beta‐glucan beverage
Number of subjects: 19
Study 19306033 — intervention group
Group type: COMPARATOR
Intervention: Beverage without fibre
Number of subjects: 19
Study 16685611 — intervention group
Group type: EXPERIMENTAL
Intervention: Pplateau respiratory pressures
Number of subjects: 34
Study 16296399 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalgae oil (0.94 g DHA/d)
Number of subjects: 104
Study 16296399 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (placebo)
Number of subjects: 104
Study 14723482 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR vaccine administered at 9-10 months
Number of subjects: 240
Study 14723482 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR vaccine administered at 15-18 months
Number of subjects: 240
Study 9469983 — intervention group
Group type: EXPERIMENTAL
Intervention: Potato + 100 g butter
Number of subjects: 12
Study 9469983 — intervention group
Group type: COMPARATOR
Intervention: Potato alone
Number of subjects: 12
Study 9469983 — intervention group
Group type: COMPARATOR
Intervention: Potato + 40 g olive oil
Number of subjects: 12
Study 9469983 — intervention group
Group type: COMPARATOR
Intervention: Potato + 50 g butter
Number of subjects: 12
Study 9469983 — intervention group
Group type: COMPARATOR
Intervention: Potato + 80 g olive oil
Number of subjects: 12
Study 9469983 — intervention group
Group type: EXPERIMENTAL
Intervention: All meals
Number of subjects: 12
Study 7893263 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg vitamin B6 (pyridoxine hydrochloride)
Number of subjects: 24
Study 7893263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2516308 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (6 g total, intraoral application six times)
Number of subjects: 0
Study 2516308 — intervention group
Group type: COMPARATOR
Intervention: Conventional irradiation method
Number of subjects: 0
Study 2516308 — intervention group
Group type: COMPARATOR
Intervention: Dynamic irradiation method
Number of subjects: 0
Study 2516308 — intervention group
Group type: COMPARATOR
Intervention: Dynamic irradiation method with Metronidazole
Number of subjects: 0
Study 2516308 — intervention group
Group type: COMPARATOR
Intervention: Irradiation twice a day
Number of subjects: 0
Study 645948 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium response scale for women in group A
Number of subjects: 53
Study 645948 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium response scale for males in group A
Number of subjects: 53
Study 645948 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-validation of scales in group B
Number of subjects: 53
Study 29107662 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 0
Study 29107662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28397104 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (OME) 40 mg administered postoperatively
Number of subjects: 20
Study 28397104 — intervention group
Group type: COMPARATOR
Intervention: Preoperative condition
Number of subjects: 20
Study 28397104 — intervention group
Group type: COMPARATOR
Intervention: Postoperative condition (6 months after surgery)
Number of subjects: 20
Study 26087791 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward-viewing linear endoscopic ultrasound (FV-EUS)
Number of subjects: 51
Study 26087791 — intervention group
Group type: COMPARATOR
Intervention: Standard oblique-viewing endoscopic ultrasound (OV-EUS)
Number of subjects: 51
Study 26087791 — intervention group
Group type: EXPERIMENTAL
Intervention: FV-EUS-guided fine-needle aspiration (FNA)
Number of subjects: 51
Study 23843495 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CHOP (obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 56
Study 23843495 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐FC (obinutuzumab plus fludarabine and cyclophosphamide)
Number of subjects: 56
Study 23843495 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CHOP
Number of subjects: 56
Study 23843495 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐FC
Number of subjects: 56
Study 19506868 — intervention group
Group type: EXPERIMENTAL
Intervention: Interlocking nailing
Number of subjects: 36
Study 19506868 — intervention group
Group type: COMPARATOR
Intervention: Dynamic compression plating
Number of subjects: 36
Study 18991471 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 75
Study 18991471 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 75
Study 18991471 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 75
Study 18991471 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 75
Study 18991471 — intervention group
Group type: COMPARATOR
Intervention: Saline 100 mL
Number of subjects: 75
Study 15845796 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine at doses of 0.05, 0.10, or 0.20 mmol/kg
Number of subjects: 95
Study 15845796 — intervention group
Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine at a dose of 0.10 mmol/kg
Number of subjects: 95
Study 15845796 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine-enhanced MR imaging
Number of subjects: 95
Study 12851058 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbolic dynamics analysis of OKN signals in patients suffering from vertigo
Number of subjects: 20
Study 12851058 — intervention group
Group type: COMPARATOR
Intervention: Symbolic dynamics analysis of OKN signals in healthy subjects
Number of subjects: 20
Study 10596916 — intervention group
Group type: EXPERIMENTAL
Intervention: TM-ILP (TNFalpha and melphalan)
Number of subjects: 64
Study 10596916 — intervention group
Group type: EXPERIMENTAL
Intervention: TIM-ILP (TNFalpha, melphalan, and IFNgamma)
Number of subjects: 64
Study 10596916 — intervention group
Group type: COMPARATOR
Intervention: Historical control (M-ILP with melphalan alone)
Number of subjects: 64
Study 8671151 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH at pulse frequency of 90 min
Number of subjects: 20
Study 8671151 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH at pulse frequency of 120 min
Number of subjects: 20
Study 8671151 — intervention group
Group type: COMPARATOR
Intervention: GnRH at pulse frequency of 60 min
Number of subjects: 20
Study 8671151 — intervention group
Group type: COMPARATOR
Intervention: GnRH at pulse frequency of 180 min
Number of subjects: 20
Study 1744962 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-1A monoclonal antibody
Number of subjects: 543
Study 6945849 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 0
Study 6945849 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 0
Study 6945849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31614361 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of fosfomycin (group A)
Number of subjects: 297
Study 31614361 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of fosfomycin (group B)
Number of subjects: 297
Study 31614361 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusion biopsy
Number of subjects: 297
Study 31614361 — intervention group
Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 297
Study 28122382 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine group
Number of subjects: 28
Study 28122382 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28